The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Targeting PARP-1 in ER-positive endocrine-resistant breast cancer.
 
Azzurra Zicarelli
No Relationships to Disclose
 
Marianna Talia
No Relationships to Disclose
 
Muriel Laine
No Relationships to Disclose
 
Rosamaria Lappano
No Relationships to Disclose
 
Marcello Maggiolini
No Relationships to Disclose
 
Geoffrey Greene
Stock and Other Ownership Interests - Olema Pharmaceuticals; Sermonix Pharmaceuticals
Consulting or Advisory Role - Sermonix Pharmaceuticals
Research Funding - Olema Pharmaceuticals; Sermonix Pharmaceuticals
Patents, Royalties, Other Intellectual Property - US Patent 12,023,321 B2, July 2, 2024 LASOFOXIFENE TREATMENT OF AROMATASE-RESISTANT ER+CANCER